局部晚期食管鳞癌术前同期放化疗疗效及预后因素分析

doi:10.3760/cma.j.cn113030-20191008-00004

摘要
图/表
参考文献(19)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的评价局部晚期食管鳞癌术前同期放化疗治疗效果和影响预后的因素。方法回顾分析2007-2017年郑州大学附属肿瘤医院收治的148例经术前同期放化疗并手术治疗的局部晚期食管鳞癌患者资料,化疗采用氟尿嘧啶+顺铂或紫杉醇+顺铂方案,放疗剂量为36~40Gy,常规分割。Kaplan-Meier法计算生存率并Logrank检验及单因素分析,Cox模型多因素分析。结果全组1、3、5年总生存率分别为74%、51%、51%,无瘤生存率分别为60%、51%、45%;中位生存期为72.4个月,无瘤生存期为60.1个月。pCR与非 pCR的1、3、5年总生存率分别为86%、70%、70%与70%、44%、43%(P=0.002),无瘤生存率分别为76%、71%、68%与53%、43%、37%(P=0.002)。pN(-)与pN(+)的1、3、5年总生存率分别为83%、56%、55%与50%、38%、38%(P=0.004),无瘤生存率分别为66%、56%、51%与43%、38%、31%(P=0.006)。多因素分析显示是否pCR和pN状态是影响总生存和无瘤生存的因素(P=0.012、0.011和P=0.025、0.033)。结论术前同期放化疗治疗局部晚期食管鳞癌疗效显著,是否pCR和pN状态是预后影响因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴小源
	杨原源
	邢文群
	李雪
	贺春语
	蒋琼
	刘劲松
	王建华

关键词 ：食管肿瘤/放射疗法, 食管肿瘤/化学疗法, 食管肿瘤/外科学, 预后

Abstract：Objective To evaluate the therapeutic effects and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Methods The clinical data of a total of 148 patients with locally advanced esophageal squamous cell carcinoma enrolled in the Affiliated Cancer Hospital of Zhengzhou University from 2007 to 2017 were retrospectively analyzed. The patients received 5-Fu/Cisplatin or Paclitaxel/Cisplatin for chemotherapies. The total treatment dose for the radiotherapy was delivered at 36-40Gy under conventional fractionation. Kaplan-Meier method was used to calculate survival rates, and Log-rank test and Cox model were performed for univariate analysis and multivariate analysis, respectively. Results The overall survival (OS) rates of 1-, 3-and 5-year were 74%, 51% and 51%, respectively, with a median survival time (MST) of 72.4 months. The carcinoma/disease-free survival (DFS) rates for 1, 3, 5 years were 60%, 51%, 45%, respectively, with a median time of 60.1 months. The 1-, 3-and 5-year OS rates of the pCR group were 86%, 70%, 70%, the ones of which in the non-pCR group were 70%, 44%, 43%, respectively (P=0.002). The 1-, 3-and 5-year DFS rates were 76%, 71%, 68% for the pCR group, and 53%, 43%, 37% for the non-pCR group, respectively (P=0.002). In pN(-) group and pN(+) group, the 1-, 3-and 5-year OS rates were 83%, 56%, 55% and 50%, 38%, 38%(P=0.004), respectively. Further, the 1-, 3-and 5-year DFS rates were 66%, 56%, 51% for the pN(-) group, and 43%, 38%, 31% for the pN(+) group (P=0.006), respectively. Multivariate analysis revealed that pCR and pN status were independent prognostic factors for OS and DFS (P=0.012, 0.011 and P=0.025, 0.033). Conclusion Neoadjuvant chemoradiotherapy demonstrated significant therapeutic effects in the treatment of locally advanced esophageal squamous cell carcinoma, while pCR and pN status served as independent prognostic factors.

Key words： Esophageal neoplasms/radiotherapy Esophageal neoplasms/chemotherapy Esophageal neoplasms/surgery Prognosis

收稿日期: 2019-10-08

基金资助:河南省医学科技攻关计划省部共建项目(201301015)

通讯作者: 王建华,Email:huajianye@sina.cn

引用本文:

吴小源,杨原源,邢文群等. 局部晚期食管鳞癌术前同期放化疗疗效及预后因素分析[J]. 中华放射肿瘤学杂志, 2020, 29(5): 337-341.

Wu Xiaoyuan,Yang Yuanyuan,Xing Wenqun et al. Analysis of the therapeutic effects and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(5): 337-341.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20191008-00004 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2020/V29/I5/337

[1] 郑荣寿, 孙可欣, 张思维, 等.2015 年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.005.
Zheng RS, Sun KX, Zhang SW, et al. Analysis of the prevalence of malignant tumors in China in 2015[J]. Chin J Oncol, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.005.
[2] Herskovic A, Russell W, Liptay M, et al. Esophageal carcinoma advances in treatment results for locally advanced disease[J]. Ann Oncol, 2011, 23(5):1095-1103. DOI:10.1093/annonc/mdr433.
[3] Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J]. Lancet Oncol, 2011, 12(7):681-692. DOI:10.1016/S1470-2045(11)70142-5.
[4] Van Hagen P, Hulshof M, Van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22):2074-2084. DOI:10.1056/NEJMoa1112088.
[5] Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010):a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27):2796. DOI:10.1200/JCO.2018.79.1483.
[6] Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1090-1098. DOI:10.1016/S1470-2045(15)00040-6.
[7] 吴小源,邢文群,刘劲松,等. 局部进展期食管鳞癌术前同期放化疗的Ⅱ期临床研究[J]. 中华放射肿瘤学杂志, 2015, 24(1):25-28. DOI:10.3760/cma.j.issn.1004-4221.2015.01.007.
Wu XY, Xing WQ, Liu JS, et al. Clinical study of the Ⅱ stage of radiotherapy and chemotherapy for local progression esophageal squamous cell carcinoma in the same period[J]. Chin J Radiat Oncol, 2015, 24(1):25-28. DOI:10.3760/cma.j.issn.1004-4221.2015.01.007.
[8] Liu SL, Yang H, Zhang P, et al. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma:A matched case-control study[J]. Radiother Oncol, 2015, 116(2):262-268. DOI:10.1016/j.radonc.2015.07.020.
[9] Van Hagen P, Wijnhoven BPL, Nafteux P, et al. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer[J]. Br J Surg, 2013, 100(2):267-273. DOI:10.1002/bjs.8968.
[10] Tong DKH, Law S, Kwong DLW, et al. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor[J]. Ann Surg Oncol, 2010, 17(8):2184-2192. DOI:10.1245/s10434-010-0995-2.
[11] Scheer RV, Fakiris AJ, Johnstone PAS. Quantifying the Benefit of a Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in the Treatment of Esophageal Cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 80(4):996-1001. DOI:10.1016/j.ijrobp.2010.03.003.
[12] Philippron A, Bollschweiler E, Kunikata A, et al. Prognostic relevance of lymph node regression after neoadjuvant chemoradiation for esophageal cancer[J]. Semin Thorac Cardiovasc Surg, 2016, 28(2):549-558. DOI:10.1053/j.semtcvs.2016.04.003.
[13] Hölscher AH, Drebber U, Schmidt H, et al. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma[J]. Ann Surg, 2014, 260(5):779-785. DOI:10.1097/SLA.0000000000000964.
[14] 谭立君,刘晓,肖泽芬,等.592例食管癌三维放疗的预后分析[J]. 中华放射肿瘤学杂志, 2015, 24(1):10-15. DOI:10.3760/cma.j.issn.1004-4221.2015.01.004.
Tan LJ, Liu X, Xiao ZF, et al. Analysis of outcomes and prognostic factors in 592 esophageal cancer patients treated with three-dimensional radiotherapy[J]. Chin J Radiat Oncol, 2015, 24(1):10-15. DOI:10.3760/cma.j.issn.1004-4221.2015.01.004.
[15] Blackham AUH, Naqvi SM, Schell MJ, et al. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer[J]. J Surg Oncol, 2018, 117(2):150-159. DOI:10.1002/jso.24808.
[16] 吴昌荣,薛恒川,朱宗海,等. 现代二野淋巴结清扫食管癌切除术的疗效分析[J]. 中华肿瘤杂志, 2009, 31(8):630-633. DOI:10.3760/cma.j.issn.0253-3766.2009.08.015.
Wu CR, Xue HC, Zhu ZH, et al. Efficacy analysis of modern wild lymph node dissection and esophageal carcinoma resection[J]. Chin J Oncol, 2009, 31(8):630-633. DOI:10.3760/cma.j.issn.0253-3766.2009.08.015.
[17] Ma J, Zhan C, Wang L, et al. The sweet approach is still worthwhile in modern esophagectomy[J]. Ann Thorac Surg, 2014, 97(5):1728-1733. DOI:10.1016/j.athoracsur.2014.01.034.
[18] Giugliano DN, Berger AC, Pucci MJ, et al. Comparative quantitative lymph node assessment in localized esophageal cancer patients after R0 resection with and without neoadjuvant chemoradiation therapy[J]. J Gastrointest Surg, 2017, 21(9):1377-1384. DOI:10.1007/s11605-017-3478-y.
[19] Talsma AK, Shapiro J, Looman CWN, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy:prognostic and therapeutic impact on survival[J]. Ann Surg, 2014, 260(5):786-793. DOI:10.1097/SLA.0000000000000965.